Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — Investor Presentation (November 2022)
33 slides from Anaptysbio's investor presentation, Nov 8, 2022
Slide 1: Corporate Overview November 2022
Corporate Overview November 2022 Nasdaq: ANAB
Slide 2: Forward-looking statements
2 This presentation and any accompanying oral presentation contain “forward‐looking” statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, inclu
Slide 3: AnaptysBio overview
3 AnaptysBio Wholly owned immune cell modulating antibodies may restore immune balance across moderate-to-severe complex diseases Significant Royalties from GSK I-O Financial Collaboration • JEMPERLI (PD-1 antagonist) 8-25% royalties plus milestones*; P3 readouts in 1L endometrial (Q4:22) and 1L ova
Slide 4: Wholly owned portfolio and anticipated milestones
4 Wholly owned portfolio developed internally using our proprietary antibody platform technology Multiple Clinical-Stage Catalysts Through 2023 Additional trial initiations within next 12 months for both checkpoint agonists across dermatological, rheumatology and gastroenterology therapeutic areas L
Slide 5: Advantages of Immune Cell Modulation in Treatment of Inflammatory Diseases
Advantages of Immune Cell Modulation in Treatment of Inflammatory Diseases
Slide 6: Moderate-to-Severe Inflammatory Diseases are Complex Leading to Shortcomings in SoC Therapies
6 Moderate-to-Severe Inflammatory Diseases are Complex Leading to Shortcomings in SoC Therapies Breadth of mechanism JAKi (IC90) JAKi (Approved doses; suboptimal PD) Cell signaling inhibitors: efficacy ceiling with AEs at most effective doses TYK2 (next gen) • Complex, heterogeneous diseases involve
Slide 7: Immune Cell Modulators May Restore Immune Balance
7 Immune Cell Modulators May Restore Immune Balance Across Moderate-to-Severe Complex Diseases JAKi (IC90) JAKi (Approved doses; suboptimal PD) Immune cell modulators: Potential increased efficacy and/or durable effect E ff ic a c y Single Cytokine blockers TYK2 (Sotyktu; suboptimal PD) Breadth of m
Slide 8: Immune Cell Modulators are a Novel Therapeutic Class
8 Immune Cell Modulators are a Novel Therapeutic Class Suppress activated immune cell types to restore immune balance CONFIDENTIAL | ANAPTYSBIO ANB033 (CD122 antagonist) ANB032 (anti-BTLA agonist) Rosnilimab (anti PD-1 agonist) A d a p ti v e I m m u n it y B cells Trm Tcon Treg/Tcon ratio In n a te
Slide 9: Checkpoint Agonists: Rosnilimab and ANB032
Checkpoint Agonists: Rosnilimab (Anti-PD-1 agonist mAb) ANB032 (Anti-BTLA agonist mAb) Autoimmune and Inflammatory Diseases
Slide 10: Anti-Inflammatory Checkpoint Agonist Antibodies
10 Anti-Inflammatory Checkpoint Agonist Antibodies • Potent checkpoint agonists for PD-1 and BTLA down regulate T cell mediated immune responses - BTLA also present on B cells and dendritic cells • Potential applicability across moderate-to severe complex diseases - Dermatology: alopecia areata, vit
Slide 11: Characteristics and Potential Differentiation of Agonist Antibodies
11 Characteristics and Potential Differentiation of Agonist Antibodies CONFIDENTIAL | ANAPTYSBIO • Iterative assay‐quantified functional activity is critical to selecting the most potent agonist across interactions of CDR and Fc characteristics In vitro and in vivo assay-based optimization • Binding
Slide 12: Rosnilimab (ANB030): Anti-PD-1 Agonist Antibody
12 • Rosnilimab: IgG1 antibody that binds to PD-1+ T cells designed to induce: - Agonistic signaling: Mimic PD-L1 function to down-regulate T cell activity in inflamed tissues - Depletion: Eliminate PD-1+ T cells in inflamed tissue and peripheral circulation via effector function • Rosnilimab has th
Slide 13: Rosnilimab Significantly Reduces IFNγ in Healthy Donor PBMCs
Rosnilimab Significantly Reduces IFNγ in Health Donor PBMCs ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ % i n h ib it io n I F N -γ (n o rm a li z e d t o i s o ty p e ) • Rosnilimab shows meaningful IFNγ inhibition beginning at low concentrations • Differentiation from Lilly’s PD-1 agonist sustained and deepens across clinical
Slide 14: Rosnilimab Phase 1 Healthy Volunteer Trial Top-Line Data
14 T Cell Population Surface Markers Average Change From Baseline Total T cells (Tcon and Treg) CD3+ <5% change Conventional T cells (Tcon) CD3+, CD25low <5% change PD-1+ Tcon cells CD3+, CD25low, PD-1+ 50% reduction High PD-1+ Tcon cells CD3+, CD25low, PD-1high 90% reduction Total regulatory T cell
Slide 15: Alopecia Areata is an Immune-Mediated Form of Hair Loss
15 Alopecia Areata is an Immune-Mediated Form of Hair Loss Inflammation-driven activation of antigen-specific PD-1+ T cells • Stress event in immune privileged healthy hair follicle • Potent immune response from keratinocyte-derived trichohyalin (TCHH) antigen specific cytokines • Activated PD-1 hig
Slide 16: Rosnilimab Treatment for Alopecia Areata
16 • T cell deactivation may ameliorate IFNɣ driven MHC class I upregulation and antigen presentation - Potentially contributes to resolution of hair follicle inflammatory cycle • Rosnilimab binding results in: - Agnostic signaling of activated PD-1+ T cells in the hair follicle • Inhibit T cell exp
Slide 17: Rosnilimab Significantly Reduces IFNγ in Alopecia Areata Patient PBMCs
17 Rosnilimab Significantly Reduces IFNγ in Alopecia Areata Patient PBMCs IF N ɣ s e c re ti o n (% o f n o r o s n il im a b ) Antibody (nM) Antibody (nM) Rosnilimab • Alopecia areata patient PBMCs stimulated with TCHH peptide antigens • Rosnilimab showed concentration dependent suppression of kera
Slide 18: Rosnilimab May Show Differentiated Efficacy and Safety in Alopecia Areata
18 Rosnilimab May Show Differentiated Efficacy and Safety for the Treatment of Alopecia Areata “Proof-of-mechanism” P2a trial may inform development in additional diseases Market Dynamics Favorable Clinical Trial Attributes • Up to ~1.5 million U.S. patients - >40% of patients estimated to have ≥50%
Slide 19: AZURE: Rosnilimab Phase 2a Trial in Alopecia Areata
19 AZURE: Rosnilimab “Proof of Mechanism” Phase 2a Trial in Moderate-to-Severe Alopecia Areata Top-line data Q1 2023 Rosnilimab 400 mg SC q4w N = 4 5 R a n d o m iz e 2 :1 Placebo Treatment Period Follow-Up Period W e e k 0 W e e k 2 4 W e e k 3 2 Population • Adult patients with moderate‐to‐severe
Slide 20: ANB032: Anti-BTLA Agonist Antibody
20 • ANB032 is an IgG4 antibody that binds to BTLA in lymphoid (T and B) cells - BTLA also present on myeloid dendritic cells and required for Treg development • ANB032 inhibits T cell proliferation and inflammatory cytokine secretion in patient- derived samples from numerous inflammatory diseases •
Slide 21: ANB032 Phase 1 Healthy Volunteer Trial Top-Line Data
21 • 96 healthy volunteers in randomized, double- blind, placebo-controlled SAD and MAD cohorts • ANB032 well-tolerated with no dose limiting tox - Most AEs mild-to-moderate, of short duration, dose independent and resolved without sequelae - No Serious Adverse Events • Favorable PK: ~2-week half-li
Slide 22: ANB033 (Anti-CD122 antagonist mAb)
ANB033 (Anti-CD122 antagonist mAb) Autoimmune and Inflammatory Diseases
Slide 23: ANB033: Anti-CD122 Antagonist Targets Pathogenic TRM Cells
Confidential 23 CD122 is a shared beta subunit of the receptors for IL-15 and IL-2 • IL-15 mediates survival of TRM cells • Both IL-15 and IL-2 mediate: - Proliferation of T cells - Inflammatory cytokine secretion (IFNγ) during T cell activation • High affinity antagonist antibody induces death in T
Slide 24: ANB033: Durable Survival in GVHD Model
Confidential 24 ANB033: Durable Survival in GVHD Model All mice treated at high-dose survived well beyond end of dosing P e rc e n t S u rv iv a l End of dosing GVHD model is biologically relevant to CD122 antagonist MoA with translation to inflammatory diseases driven by pathogenic TRM and Treg imb
Slide 25: Imsidolimab (Anti-IL-36R antagonist mAb) Generalized Pustular Psoriasis
Imsidolimab (Anti-IL-36r antagonist mAb) Generalized Pustular Psoriasis (GPP)
Slide 26: Generalized Pustular Psoriasis (GPP)
26 • GPP is a systemic, life-threatening inflammatory disease characterized by widespread pustules - Associated with unregulated IL-36 signaling - Patients have a high fever and elevated levels of serum CRP and inflammatory cytokines (e.g., IL-8) - Severe GPP patients can die from cardio-pulmonary f
Slide 27: Imsidolimab is an IL-36 Receptor Antagonist
Normal Individuals IL-36 cytokine signaling balanced by function IL-36 receptor antagonist Disease Patients Uncontrolled signaling due to dysfunctional IL-36 receptor antagonist or elevated IL-36 cytokine levels Treated Patients Anti-IL-36R antibody has the potential to dampen disease by blocking th
Slide 28: Imsidolimab Phase 2 GPP trial results
28 • Imsidolimab 750mg IV loading dose + 100mg SC q4w maintenance dose • Rapid and sustained efficacy through week 16 – 6 of 8 (75%) patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) – Early reduction of erythema with skin pustules by week 1; sustained r
Slide 29: GEMINI-1 and GEMINI-2 Phase 3 trial design
29 Patient Population R a n d o m iz a ti o n n = 4 5 * W e e k 0 Key Endpoints • Male and female subjects 18 to 80 years of age • Clinically confirmed diagnosis of GPP as per ERASPEN definition • Baseline Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) score of at least moderate
Slide 30: GSK Immuno-Oncology Financial Collaboration
GSK Immuno-Oncology Financial Collaboration JEMPERLITM (dostarlimab, anti-PD-1 Antagonist) Cobolimab (GSK4069889, anti-TIM-3 Antagonist) GSK4074386 (TSR-033, anti-LAG-3 Antagonist)
Slide 31: JEMPERLI royalties and Sagard monetization
31 JEMPERLI (anti‐PD‐1 antagonist) GSK anticipates ~$1.2‐2.4B peak annual sales for JEPMPERLI in currently approved indications and anticipated 1L endometrial/ovarian approvals* • JEMPERLI 12‐25% royalties on annual net sales ≥ $1B • JEMPERLI $75mm commercial milestone on annual net sales ≥ $1B In 2
Slide 32: GSK clinical development programs for JEMPERLI, cobolimab and GSK4074386
Endometrial 1L Advanced/Recurrent: RUBY (n=740) PD-1 mono or PD-1/ZEJULA dMMR Pan-Tumor Ovarian 1L Ovarian: FIRST (n=1405) PD-1/ZEJULA combo OPAL (n=41) PD-1/ZEJULA/bevacizumab combo NSCLC JASPER (n=53) PD-1/ZEJULA combo PERLA (n=240): vs. Keytruda in 1L (chemo combo) (Data at ESMO I-O Dec. 2022) CO
Slide 33: y ; > « XN a . N » J y ‘ \ ;
y ; > « XN a . N » J y ‘ \ ; , | y AnaptysBi oW We \ y | ff | f y f